China Biologic Products Holdings, Inc. (CBPO)
| Previous close | 118.06 |
| Open | 118.00 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1400 |
| Day's range | 117.50 - 118.07 |
| 52-week range | 97.91 - 120.01 |
| Volume | 81,653 |
| Avg. volume | 167,690 |
| Market cap | 4.544B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 33.00 |
| EPS (TTM) | 3.57 |
| Earnings date | 10 Mar 2021 - 15 Mar 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 102.78 |
- PR Newswire
China Biologic Announces Shareholders' Approval of Merger Agreement
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement"), among the Company, CBPO Holdings Limited ("Parent") and CBPO Group Limited ("Merger Sub"), pursuant to which, Merger Sub will be merged with and into the Company with the Company continuing as the surviving company and becoming a wholly owned subsidiary of Parent (the "Merger"), the plan of merger (the "Plan of Merger") required to be filed with the Registrar of Companies of the Cayman Islands, and the transactions contemplated thereby, including the Merger.
- PR Newswire
China Biologic Announces Extraordinary General Meeting of Shareholders
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has called an extraordinary general meeting of shareholders (the "EGM") to be held on March 1, 2021 at 10:00 a.m. (Beijing time), at the principal office of the Company located at 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing, China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement"), among the Company, CBPO Holdings Limited ("Parent") and CBPO Group Limited ("Merger Sub"), the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the "Plan of Merger") and the transactions contemplated thereby, including the Merger (as defined below).
- Motley Fool
China Biologic Products Inc (CBPO) Q3 2020 Earnings Call Transcript
China Biologic announced its third quarter 2020 financial results on November 24th, 2020, after the market closed. Today, you will hear from China Biologic's Chairman and CEO, Mr. Joseph Chow, who will start off the call with a review of the Company's basic operating results and report recent developments. China Biologic's CFO, Mr. Ming Yang, will be available during the Q&A session following the prepared remarks.
